title: In brief: intravenous ondanstron (Zofran) 32 mg withdrawn.
mesh_terms: D000932:Antiemetics / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced*; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D017294:Ondansetron / Q000008:administration & dosage / Q000009:adverse effects*; D057051:Product Recalls and Withdrawals; D016171:Torsades de Pointes / Q000139:chemically induced*; D014481:United States; D014486:United States Food and Drug Administration; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D017294:Ondansetron